GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal
GSK has obtained exclusive global rights to develop and commercialize Syndivia's preclinical antibody-drug conjugate (ADC) targeting metastatic castration-resistant prostate cancer (mCRPC) through a licensing agreement valued up to £268 million ($357 million)123457.
The deal includes an upfront payment to Syndivia and additional milestone payments tied to development and commercial achievements237.
Syndivia's ADC, based on its GeminiMab platform, has demonstrated enhanced anti-tumor activity and an encouraging safety profile in preclinical studies, reducing tumor size without significant toxicity1234.
GSK intends for this ADC candidate to address a critical unmet need in advanced prostate cancer, aiming to offer a more targeted therapy where there are currently limited options124.
This acquisition bolsters GSK's oncology pipeline, complementing its other ADC programs such as GSK'227, and aligns with the company's ongoing expansion in tumor-targeted therapies345.
The agreement arrives during a leadership transition at GSK, with outgoing CEO Emma Walmsley overseeing the deal1.
Sources:
1. https://www.pharmiweb.com/pwtoday-story/gsk-secures-rights-to-syndivia-s-adc-asset-for-prostate-cancer
2. https://pharma.economictimes.indiatimes.com/news/pharma-industry/gsk-acquires-syndivias-preclinical-cancer-candidate-for-over-355-mn/124867199
3. https://www.pharmexec.com/view/gsk-357-million-exclusive-agreement-syndivia-antibody-drug-conjugate
4. https://www.morningstar.com/news/dow-jones/20251027869/gsk-acquires-rights-to-prostate-cancer-candidate-for-up-to-357-million
5. https://www.pharmaceutical-technology.com/news/gsk-targets-syndivias-prostate-cancer-adc-in-268m-buy/